Alopecia study: Scalp cooling with hairstyle
Official title Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
ClinicalTrials.gov ID: NCT05213936
What this study is testing
- What it's testing
- The study tests two hairstyling methods to improve how well scalp cooling prevents hair loss during chemotherapy. It also looks at long‑term hair loss and the genes that might predict success.
- Who it's for
- People of color who are receiving chemotherapy for breast cancer or non‑small cell lung cancer.
- What's involved
- Participants will try either cornrows/braids/twists or a water/conditioner wash before wearing a scalp cooling cap during chemo. After treatment, they will be followed for up to 6 months and give hair samples for gene testing.
- Time commitment
- The study lasts up to 6 months after chemotherapy, with visits for cap fitting, hair loss monitoring, and hair sample collection.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age \>= 18 years
- Female
- Hair type 3 (curly) or type 4 (kinky)
- Diagnosis of breast cancer or non-small cell lung cancer (NSCLC) or gynecologic cancer stage I-IV
- Patient will be starting \>= 4 cycles of taxane-based chemotherapy treatment for curative intent after enrollment a.
You likely can't join if
- Hair type other than 3 or 4
- Male
- Use of hair weave or extensions without plans to remove
- Concurrent malignancy including hematologic malignancies (i.e. leukemia or lymphoma)
- Alopecia Common Terminology Criteria for Adverse Events \> grade 1 at baseline
- Past chemotherapy administration if past treatment was \<= 10 years ago
See the full eligibility criteria
- Age \>= 18 years
- Female
- Hair type 3 (curly) or type 4 (kinky)
- Diagnosis of breast cancer or non-small cell lung cancer (NSCLC) or gynecologic cancer stage I-IV
- Patient will be starting \>= 4 cycles of taxane-based chemotherapy treatment for curative intent after enrollment a. Concurrent HER, cisplatin, cyclophosphamide therapies and doxorubicin therapies allowed
- Eastern Cooperative Oncology Group (ECOG) 0-2: fully active, restrictive in physically strenuous activity, ambulatory and capable of self-care
- Hair type other than 3 or 4
- Male
- Use of hair weave or extensions without plans to remove
- Concurrent malignancy including hematologic malignancies (i.e. leukemia or lymphoma)
- Alopecia Common Terminology Criteria for Adverse Events \> grade 1 at baseline
- Past chemotherapy administration if past treatment was \<= 10 years ago
- History of migraines or cluster headaches, anorexia, severe anemia, uncontrolled diabetes, hepatitis, thyroid dysfunction, cold urticaria, cold agglutinin disease, scalp metastases
- Planned bone marrow ablation chemotherapy or skull irradiation
- Pregnant patient
The study team makes the final eligibility decision.
Where it is enrolling
- The Bronx, New York, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at The Bronx, New York, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.